A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Drugs like Ozempic and Wegovy — known as glucagon-like peptide-1 receptor agonists, or GLP-1s — have made headlines and surged in popularity for their unique ability to help patients lose weight by ...

Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

DD01 is a liver-targeted, long-acting, dual GLP-1/glucagon receptor agonist previously shown to rapidly resolve hepatic steatosis, improve glycemic control, and reduce body weight in subjects with ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...